Alicandro, G.; Daccò, V.; Cariani, L.; Rosazza, C.; Sciarrabba, C.S.; Ferraro, F.; Lanfranchi, C.; Medino, P.; Girelli, D.; Colombo, C.
Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies. Biomedicines 2022, 10, 1998.
https://doi.org/10.3390/biomedicines10081998
AMA Style
Alicandro G, Daccò V, Cariani L, Rosazza C, Sciarrabba CS, Ferraro F, Lanfranchi C, Medino P, Girelli D, Colombo C.
Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies. Biomedicines. 2022; 10(8):1998.
https://doi.org/10.3390/biomedicines10081998
Chicago/Turabian Style
Alicandro, Gianfranco, Valeria Daccò, Lisa Cariani, Chiara Rosazza, Calogero Sathya Sciarrabba, Federica Ferraro, Chiara Lanfranchi, Paola Medino, Daniela Girelli, and Carla Colombo.
2022. "Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies" Biomedicines 10, no. 8: 1998.
https://doi.org/10.3390/biomedicines10081998
APA Style
Alicandro, G., Daccò, V., Cariani, L., Rosazza, C., Sciarrabba, C. S., Ferraro, F., Lanfranchi, C., Medino, P., Girelli, D., & Colombo, C.
(2022). Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies. Biomedicines, 10(8), 1998.
https://doi.org/10.3390/biomedicines10081998
